SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma’s arm gets US FDA approval for AshlynaTM Tablets

25 Feb 2015 Evaluate

Glenmark Generics Inc (GGI), a step down subsidiary of Glenmark Pharmaceuticals has received US Food and Drug Administration (US FDA) approval and introduced AshlynaTM (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Extended-Cycle Oral Contraceptive Tablets, the generic equivalent of Seasonique by Teva Women’s Health, in US.

Seasonique is indicated for use by women to prevent pregnancy. According to IMS Health sales data for the 12 month period ending December 2014, the Seasonique market achieved annual sales of approximately $159.1 million.

The approval marks Glenmark’s 10th oral contraceptive and first extended-cycle oral contraceptive authorized for distribution by the U.S. FDA. Glenmark is planning to commence shipping of Ash lynaTM immediately.

Glenmark’s current portfolio consists of 94 products authorized for distribution in the U.S. marketplace and 75 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×